Rockefeller Capital Management L.P. Bluebird Bio, Inc. Transaction History

Rockefeller Capital Management L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$3.75 - $7.39 $258 - $509	-69 Reduced 84.15%	13 $0
Q2 2022 Aug 12, 2022	BUY	$2.94 - $5.23 $241 - $428	82 New	82 $0
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $15,904 - $28,950	-1,775 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$11.24 - $21.0 $899 - $1,680	80 Added 4.72%	1,775 $33,000
Q2 2021 Aug 10, 2021	BUY	$18.04 - $22.09 $3,608 - $4,418	200 Added 13.38%	1,695 $54,000
Q1 2021 May 11, 2021	SELL	$16.59 - $33.89 $73,742 - $150,641	-4,445 Reduced 74.83%	1,495 $45,000
Q4 2020 Feb 12, 2021	SELL	$27.5 - $37.92 $3,107 - $4,284	-113 Reduced 1.87%	5,940 $256,000
Q3 2020 Nov 13, 2020	SELL	$34.44 - $43.75 $170,719 - $216,868	-4,957 Reduced 45.02%	6,053 $326,000
Q2 2020 Aug 12, 2020	BUY	$27.12 - $45.97 $259,158 - $439,289	9,556 Added 657.22%	11,010 $672,000
Q1 2020 May 12, 2020	BUY	$26.16 - $63.5 $1,543 - $3,746	59 Added 4.23%	1,454 $67,000
Q2 2019 Aug 09, 2019	SELL	$75.84 - $105.21 $606 - $841	-8 Reduced 0.57%	1,395 $177,000
Q1 2019 May 10, 2019	BUY	$64.44 - $104.11 $515 - $832	8 Added 0.57%	1,403 $221,000
Q4 2018 Feb 12, 2019	BUY	$59.1 - $93.26 $82,444 - $130,097	1,395 New	1,395 $138,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.